Alternating Cycles of Sunitinib and Everolimus Do Not Prevent Resistance in mRCC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Randomised Phase II Study Comparing Alternating Cycles of Sunitinib and Everolimus Versus Standard Sequential Administration in First-Line Metastatic Renal Carcinoma (SUNRISES Study)
BJU Int 2020 Jul 12;[EPub Ahead of Print], A Rodriguez-Vida, A Bamias, E Esteban, MI Saez, M Lopez-Brea, D Castellano, C Caballero, J Luis Gonzalez-Larriba, E Calvo, S Macia, A Ravaud, J BellmuntFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.